Recipharm, a contract development and manufacturing organisation (CDMO) has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD).
The new service is designed to offer pharmaceutical companies access to Recipharm’s serialisation capabilities as a standalone service due to concerns that many may not be ready for the February 2019 compliance deadline.
Moving forward Recipharm will be able to add 2D codes, human readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.
Recipharm has delivered over 1.3 million serialised and aggregated packs to markets such as China, South Korea, Saudi Arabia and Turkey, and 0.5 million packs to the US, where serialisation regulations are currently in place.
Staffan Widengren, Director of Corporate Projects at Recipharm and Head of the Global Steering Committee for the serialisation programme said: ”This new offering is the latest phase in our company-wide serialisation project which was launched in 2016 following a EUR 40 million investment… Implementing these measures independently across packaging lines to ensure compliance is a relatively straightforward process when using offline equipment.”